AUPH

Over the past six months, Aurinia's stock saw a +6.80% increase on August 19, 2026, after settling patent litigation with Teva, delaying generic competition for LUPKYNIS until December 2036. On August 6, 2026, the stock increased by +6.19% following Q2 2026 financial results, which exceeded EPS estimates and showed robust LUPKYNIS revenue growth of $79.4 million, up 19% year-over-year, with full-year revenue guidance reiterated at $315 million to $325 million. On July 6, 2026, the stock decreased by -0.77% after the announcement of the PRESERVE study for LUPKYNIS. On May 7, 2026, the stock decreased by -6.80% after Q1 2026 financial results, which reported LUPKYNIS net product sales of $73.6 million, up 23% from 2025. Minor changes of -2.03% and -3.19% occurred on March 30, 2026, and February 26, 2026, respectively. Overall, the stock price gained 39.9% over the past 12 months but decreased by 2.24% in the past month.